Organon's VTAMA (tapinarof) cream, 1% shows early and consistent response in children 2+ with atopic dermatitis, including with atopic comorbidities.
Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2ZORYVE cream 0.05% ...
New data from Phase 3 studies show once-daily ZORYVE cream helped reduce sleep disruptions in individuals with atopic dermatitis aged ≥2 yearsNew ...
Dry skin isn't always harmless. Dr Soma Sarkar of Skin Beyond Borders explains how to tell the difference between simple ...
Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.
TENS of thousands of people in England suffering from debilitating eczema could soon be free of agonising symptoms after a ...
Eczema, a chronic skin condition causing itching and inflammation, affects people of all ages. It manifests in various forms ...
New clinical data demonstrate Zoryve's effectiveness in treating atopic dermatitis, reducing sleep disruptions and maintaining disease control with minimal adverse events across all ages.
Organon posts Q3 EPS of $1.01, topping estimates, trims 2025 sales outlook, and highlights positive Vtama data in children ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback